Skip to search formSkip to main contentSkip to account menu

OMP-59R5

Known as: MoAb OMP-59R5, OMP 59R5 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tarextumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract A41: Use of patient-derived tumor xenografts (PDX) for discovery and development of an anti-Notch2/3 monoclonal antibody targeting cancer stem cells
Accumulating evidence has suggested that tumors may arise and grow as a result of the formation of a subset cell population… 
Review
2016
Review
2016
Abstract A42: Using a PDX tumor bank to screen for cancer stem cell therapies
OncoMed Pharmaceuticals is focused on discovering novel therapies that target cancer stem cells (CSCs), specifically those which… 
2015
2015
Abstract A33: Combined therapy of a novel anti-NOTCH2/3 antibody with paclitaxel inhibits tumor growth in a patient-derived breast tumor xenograft
Cancer stem cells (CSCs) have been identified as the small subpopulation of cells in many cancers and are thought to be… 
2014
2014
Abstract 3048: OMP-59R5 (Anti-Notch2/3) inhibits tumor growth and reduces cancer stem cell frequency in patient derived SCLC xenografts
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Small cell lung cancer (SCLC) is a devastating disease… 
2014
2014
Abstract 910: NOTCH3 expression is predictive of efficacy in pancreas tumor models treated with OMP-59R5, a monoclonal antibody targeting the NOTCH2 and NOTCH3 receptors
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA The Notch signaling pathway regulates key functions during… 
2012
2012
A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors.
3025 Background: The Notch pathway plays a central role in embryonic development, the regulation of stem and progenitor cells… 
2012
2012
28 A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid Tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)